GlassScriptPhysician profile
Nina Williams
NPI 1518370337
$4,599.93
in general payments reported to CMS, 2019-2025
33 companies · $618 in 2025
The $618 reported for 2025 was less than what a typical Advanced Heart Failure and Transplant Cardiology provider received nationally (typical 2025 total: $1,046).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $310 · 2020: $226 · 2021: $142 · 2022: $951 · 2023: $1,201 · 2024: $1,151 · 2025: $618.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,970.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,195.83 | 2019-2025 | Thoratec Heartmate 3 Lvas Implant Kit, Aveir, Xience Skypoint |
| Novartis Pharmaceuticals Corporation | $604.77 | 2022-2025 | |
| Abiomed | $501.99 | 2023-2024 | Impella |
| Boston Scientific Corporation | $232.92 | 2022-2025 | Watchman Flx, Watchman Access System, General - Therapies |
| Janssen Pharmaceuticals, INC | $203.69 | 2021-2022 | |
| Amgen INC. | $179.05 | 2021-2025 | Repatha, Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $159.55 | 2021-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $130.90 | 2021-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $125.95 | 2022-2025 | Ozempic, Wegovy, Rybelsus |
| Pfizer INC. | $125.05 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $119.12 | 2022-2025 | Verquvo, Capvaxive |
| Alnylam Pharmaceuticals INC. | $111.83 | 2023-2025 | Onpattro |
| Astrazeneca Pharmaceuticals LP | $98.96 | 2022-2025 | Farxiga, Wainua, Andexxa |
| Bayer Healthcare Pharmaceuticals INC. | $78.37 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $73.54 | 2022-2025 | Jardiance |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $72.97 | 2024 | |
| Cardinal Health 200 LLC | $64.93 | 2019 | |
| Sanofi-Aventis U.S. LLC | $64.88 | 2022-2023 | |
| Esperion Therapeutics, INC. | $57.24 | 2024 | Nexletol |
| Akcea Therapeutics, INC. | $49.56 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $44.85 | 2022-2023 | Opsumit |
| Vivaquant INC, Dba Rhythm Express | $41.80 | 2024 | Rhythm Express |
| Angiodynamics, INC. | $38.88 | 2025 | Alphavac |
| Philips North America LLC | $38.74 | 2024-2025 | (Ck4) Mcot, Mcot |
| Daiichi Sankyo INC. | $35.60 | 2025 | Injectafer |
| Impulse Dynamics (USA) INC. | $29.10 | 2023-2025 | Optimizer, Optimizer |
| Irhythm Technologies, INC. | $23.24 | 2022 | |
| Baxter Healthcare | $20.05 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Pharmacosmos Therapeutics INC. | $16.45 | 2024 | Monoferric |
| Lilly USA, LLC | $16.10 | 2025 | Zepbound |
| Amarin Pharma, INC. | $15.96 | 2022 | |
| Nuwellis, INC. | $14.49 | 2021 | |
| Chiesi USA, INC. | $13.57 | 2023 | Kengreal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nina Williams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.